Thursday, April 19, 2012
Massachusetts researchers have developed
an RNA-based method for the rapid detection of pathogens in clinical samples.1
The team is now designing an integrated diagnostic platform that contains a
comprehensive set of bacterial, viral and fungal probes to help pinpoint
specific pathogens and their degree of drug resistance more efficiently than
T. SciBX 5(16);
Published online April 19, 2012
1. Barczak, A.K. et al. Proc. Natl.
Acad. Sci. USA; published online
April 2, 2012; doi:10.1073/pnas.1119540109
Contact: Deborah T. Hung, Broad Institute of MIT and Harvard,
2. Sangurdekar, D.P. et al. Genome Biol. 7, R32 (2006)
3. Polley, S.D. et al. J. Clin.
Microbiol. 48, 2866-2871 (2010)
4. Francois, P. et al. FEMS Immunol.
Med. Microbiol. 62, 41-48 (2011)
5. Boehme, C.C. et al. N. Eng. J.
Med. 363, 1005-1015 (2010)
6. Nistico, L. et al. J. Clin.
Microbiol. 49, 1411-1420 (2011)
AND INSTITUTIONS MENTIONED
Brigham and Women's Hospital, Boston, Mass.
Broad Institute of MIT and Harvard, Cambridge, Mass.
Drexel University College of Medicine, Philadelphia, Pa.
Foundation for Innovative New Diagnostics, Geneva, Switzerland
Harvard Medical School, Boston, Mass.
Luminex Corp. (NASDAQ:LMNX), Austin, Texas
Massachusetts General Hospital, Boston, Mass.
T2 Biosystems Inc., Lexington, Mass.